Taha Ahmedna

ORCID: 0000-0003-4786-2292
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer, Hypoxia, and Metabolism
  • Epigenetics and DNA Methylation
  • Pancreatic and Hepatic Oncology Research
  • Health Literacy and Information Accessibility
  • Immune Cell Function and Interaction
  • Cancer, Lipids, and Metabolism
  • Immunotherapy and Immune Responses
  • Consumer Attitudes and Food Labeling
  • Erythrocyte Function and Pathophysiology
  • Sodium Intake and Health
  • RNA modifications and cancer
  • CAR-T cell therapy research
  • Dietetics, Nutrition, and Education

Sidney Kimmel Comprehensive Cancer Center
2023-2025

Johns Hopkins University
2022-2025

Johns Hopkins Medicine
2023

Tuberculosis (TB) remains among the leading infectious causes of death. Due to limited number antimicrobials in TB drug discovery pipeline, interest has developed host-directed approaches improve treatment outcomes. C-C motif chemokine-like receptor 2 (CCRL2) is a unique seven-transmembrane domain that upregulated by inflammatory signals and mediates leucocyte migration. However, little known about its role infection. Here, we show Mycobacterium tuberculosis (Mtb) infection increases CCRL2...

10.3389/fimmu.2025.1501329 article EN cc-by Frontiers in Immunology 2025-03-20

Cell-based immunotherapy for glioblastoma (GBM) encounters major challenges due to the infiltration-resistant and immunosuppressive tumor microenvironment (TME). γδ T cells, unconventional cells expressing characteristic cell receptor, have demonstrated promise in overcoming these challenges, suggesting great immunotherapeutic potential. This review presents role of GBM proposes several research avenues future studies. Using PubMed, ScienceDirect, JSTOR databases, we performed a literature...

10.3390/cancers15245784 article EN Cancers 2023-12-10

Abstract The purpose of this paper is to evaluate the quality information and guidance on dietary sodium reduction available consumer‐facing websites. Google Trends was used identify five most‐used search terms related reduction. For each term, websites first two pages were collected ( n = 18–20). Of 93 collected, 24 excluded due defective links, duplicate websites, or not being consumer‐focused. remaining 69 evaluated using a novel instrument, JHU‐SALT, that includes 14 questions topics...

10.1111/jch.14572 article EN cc-by Journal of Clinical Hypertension 2022-09-29

Nearly 30% of Pancreatic ductal adenocarcinoma (PDAC)s exhibit a marked overexpression Monocarboxylate Transporter 1 (MCT1) offering unique opportunity for therapy. However, biochemical inhibitors MCT1 have proven unsuccessful in clinical trials. In this study we present an alternative approach using 3-Bromopyruvate (3BP) to target overexpressing PDACs. 3BP is cytotoxic agent that known be transported into cells via MCT1, but its usefulness has been hampered by difficulties delivering the...

10.7554/elife.94488.1 preprint EN 2024-03-19

Nearly 30% of Pancreatic ductal adenocarcinoma (PDAC)s exhibit a marked overexpression Monocarboxylate Transporter 1 (MCT1) offering unique opportunity for therapy. However, biochemical inhibitors MCT1 have proven unsuccessful in clinical trials. In this study we present an alternative approach using 3-Bromopyruvate (3BP) to target overexpressing PDACs. 3BP is cytotoxic agent that known be transported into cells via MCT1, but its usefulness has been hampered by difficulties delivering the...

10.7554/elife.94488 preprint EN 2024-03-19

Nearly 30% of Pancreatic ductal adenocarcinoma (PDAC)s exhibit a marked overexpression Monocarboxylate Transporter 1 (MCT1) offering unique opportunity for therapy. However, biochemical inhibitors MCT1 have proven unsuccessful in clinical trials. In this study we present an alternative approach using 3-Bromopyruvate (3BP) to target overexpressing PDACs. 3BP is cytotoxic agent that known be transported into cells via MCT1, but its usefulness has been hampered by difficulties delivering the...

10.7554/elife.94488.2 preprint EN 2024-09-25

Abstract Nearly 30% of Pancreatic ductal adenocarcinoma (PDAC)s exhibit a marked overexpression Monocarboxylate Transporter 1 (MCT1) offering unique opportunity for therapy. However, biochemical inhibitors MCT1 have proven unsuccessful in clinical trials. In this study we present an alternative approach using 3-Bromopyruvate (3BP) to target overexpressing PDACs. 3BP is cytotoxic agent that known be transported into cells via MCT1, but its usefulness has been hampered by difficulties...

10.1101/2023.07.23.550207 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2023-07-25

Objective: To evaluate the quality of information and guidance on dietary sodium reduction available consumer-facing websites. Methods: Google Trends was used to identify five most search terms related reduction. For each term, top 20 websites were collected. Of 93 unique websites, 69 met inclusion criteria. Each website evaluated using 14 questions in three categories ("information", "guidance", “accuracy”). question, scored a 3-step scale (“none”, “somewhat”, “adequate”). Results: Overall,...

10.1161/circ.145.suppl_1.p056 article EN Circulation 2022-03-01
Coming Soon ...